We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

69 hedge funds and large institutions have $169M invested in Autolus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

31% more capital invested

Capital invested by funds: $129M → $169M (+$39.9M)

10% more funds holding

Funds holding: 63 → 69 (+6)

4.29% more ownership

Funds ownership: 33.82% → 38.11% (+4.3%)

Holders
69
Holders Change
+6
Holders Change %
+9.52%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
22
Reduced
13
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$16.9M
2
FM
Frazier Management
Washington
+$14.2M
3
NCM
Nantahala Capital Management
Connecticut
+$11.1M
4
Goldman Sachs
Goldman Sachs
New York
+$3.97M
5
SCM
Sio Capital Management
New York
+$3.67M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$13M
2
DM
Deerfield Management
New York
-$12.3M
3
OM
Opaleye Management
Massachusetts
-$12.1M
4
BBA
Baker Bros. Advisors
New York
-$2.65M
5
BlackRock
BlackRock
New York
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital World Investors
1
Capital World Investors
California
$19.6M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$18.3M +$16.9M +2,721,085 +6,530%
TAM
3
TFG Asset Management
Cayman Islands
$16.6M +$399K +64,286 +3%
FM
4
Frazier Management
Washington
$15.2M +$14.2M +2,283,966 New
Fidelity Investments
5
Fidelity Investments
Massachusetts
$13.7M – – –
NCM
6
Nantahala Capital Management
Connecticut
$11.9M +$11.1M +1,793,500 New
Schroder Investment Management Group
7
Schroder Investment Management Group
United Kingdom
$11.1M – – –
IC
8
Ikarian Capital
Texas
$9M +$621K +100,000 +8%
JP Morgan Chase
9
JP Morgan Chase
New York
$4.99M +$1.22M +196,595 +35%
Millennium Management
10
Millennium Management
New York
$4.82M +$3.08M +496,663 +217%
AI
11
Alphabet Inc
California
$4.64M – – –
PG
12
Pendal Group
Australia
$4.6M +$2.56M +411,685 +339%
Goldman Sachs
13
Goldman Sachs
New York
$4.32M +$3.97M +639,002 +5,559%
SCM
14
Sio Capital Management
New York
$3.93M +$3.67M +591,870 New
EP
15
Eversept Partners
New York
$3.14M +$2.94M +473,074 New
SM
16
Sabby Management
Florida
$2.66M -$777K -125,180 -24%
CAM
17
Cormorant Asset Management
Massachusetts
$2.6M -$186K -30,000 -7%
GIM
18
Granahan Investment Management
Massachusetts
$2.4M +$124K +20,008 +6%
Marshall Wace
19
Marshall Wace
United Kingdom
$1.98M +$1.23M +198,736 +201%
Morgan Stanley
20
Morgan Stanley
New York
$1.85M +$851K +137,038 +97%
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$1.39M – – –
BFM
22
Boothbay Fund Management
New York
$1.27M +$260K +41,908 +28%
Wells Fargo
23
Wells Fargo
California
$950K +$452K +72,868 +104%
VF
24
Virtu Financial
New York
$863K +$806K +129,907 New
Allianz Asset Management
25
Allianz Asset Management
Germany
$815K +$761K +122,680 New
1
2 3 4

AUTL Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2021, worth a combined $169M — up 31% from $129M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AUTL positions and 17 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.9M. The largest seller was Capital International Investors, exiting entirely with an estimated $13M sold.

  • 69 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2021, up from 63 in Q1 2021.
  • Funds reported $169M of Autolus Therapeutics stock for Q2 2021, up 31% quarter-over-quarter.
  • 23 funds opened new Autolus Therapeutics positions in Q2 2021 and 17 closed out, a net change of +6 holders.
  • The largest Autolus Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $16.9M added.
  • The largest Autolus Therapeutics seller in Q2 2021 was Capital International Investors, an estimated $13M sold.

Based on aggregated 13F filings for Q2 2021.